August 12, 2025
2 min watch
Key takeaways:
- The phase 2 ACUITY trial met its primary safety endpoint and key secondary endpoints.
- Privosegtor preserved retinal nerve fiber layer and ganglion cell inner plexiform layer thickness.
LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, discusses the phase 2 ACUITY trial investigating privosegtor for neuroprotection in patients with optic neuritis.
According to Khanani, privosegtor, also known as OCS-05 (Oculis), is “a neuroprotective candidate activating neurotrophic signaling pathways supporting neuronal and axonal survival and preservation.” Patients were treated with an intravitreal formulation of privosegtor and steroids or placebo and steroids.
Results showed that privosegtor achieved its primary safety endpoint and key secondary endpoints. It also demonstrated functional vision improvements, including an 18-letter difference in low contrast visual acuity at 3 months.
Anatomic benefits included less decrease in retinal nerve fiber layer and ganglion cell inner plexiform layer thickness.
“This molecule has a lot of potential in diabetic retinopathy and geographic atrophy in terms of preserving retinal ganglion cells and axons,” Khanani told Healio. “I’m looking forward to more studies on this in the near future in optic neuritis, multiple sclerosis as well as retinal diseases.”
Sources/Disclosures
Collapse
Khanani A. Efficacy and safety of privosegtor in acute optic neuritis: Results from a multicenter, randomized, double blinded study (ACUITY). Presented at: Clinical Trials at the Summit; June 21, 2025; Las Vegas.
Disclosures:
Khanani reports consulting for Oculis.
